Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlook
TipRanksApr 25 12:35 ET
Prime Medicine Analyst Ratings
BenzingaApr 23 13:13 ET
Buy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic Progress
TipRanksApr 22 07:55 ET
Prime Medicine Analyst Ratings
BenzingaApr 22 07:48 ET
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
TipRanksApr 12 07:10 ET
Prime Medicine Analyst Ratings
BenzingaApr 8 17:18 ET
Prime Medicine Analyst Ratings
BenzingaApr 2 16:24 ET
Analysts' Top Healthcare Picks: Prime Medicine, Inc. (PRME), Alcidion Group Limited (AU:ALC)
TipRanksMar 20 05:07 ET
Buy Rating Justified: Prime Medicine's Promising Clinical Prospects and Innovative Gene Editing Technology Poised for Growth
TipRanksMar 12 07:06 ET
Prime Medicine Analyst Ratings
BenzingaMar 5 12:03 ET
Buy Rating Affirmed for Prime Medicine, Inc. on Anticipated IND Filing and Strong Gene Editing Pipeline
TipRanksMar 4 07:26 ET
Citigroup Initiates Coverage On Prime Medicine With Neutral Rating, Announces Price Target of $10
BenzingaDec 8, 2023 07:38 ET
Prime Medicine Analyst Ratings
BenzingaDec 8, 2023 07:37 ET
Prime Medicine, Inc. (PRME) Earns Buy Rating: Preclinical Developments and Financial Strength Underline Investment Potential
TipRanksNov 7, 2023 16:35 ET
JP Morgan Maintains Overweight on Prime Medicine, Lowers Price Target to $26
BenzingaNov 7, 2023 15:21 ET
Prime Medicine Analyst Ratings
BenzingaNov 7, 2023 15:20 ET
Prime Medicine's Promising Outlook: Buy Rating Justified by Preclinical Success, Potential Partnerships, and Healthy Financials
TipRanksNov 7, 2023 07:19 ET
Analysts Offer Insights on Healthcare Companies: Aslan Pharmaceuticals (ASLN), Prime Medicine, Inc. (PRME) and HealthStream (HSTM)
TipRanksOct 25, 2023 07:30 ET
BMO Capital Initiates Coverage On Prime Medicine With Outperform Rating, Announces Price Target of $19
BenzingaOct 9, 2023 07:09 ET
Prime Medicine Analyst Ratings
BenzingaOct 9, 2023 07:08 ET
No Data
No Data